Article PDF first page preview

First page of Risk Factors for Acute Cholangitis Caused by Extended-Spectrum Beta-Lactamase and AmpC-Producing Organisms

Introduction Prompt antibiotic administration is essential in the management of acute cholangitis (AC). In selecting initial antibiotics, it is important to consider both the severity of the condition and the antimicrobial activity spectrum, particularly against major resistant bacteria. Extended-spectrum β-lactamases and AmpC productions are key factors in pathogen resistance; however, knowledge of patient characteristics in cholangitis management remains limited. We aimed to analyze risk factors for extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) and for chromosomally-mediated AmpC-producing Enterobacteriaceae (CAE). Methods This study retrospectively analyzed patients with AC who underwent endoscopic retrograde cholangiopancreatography (ERCP) at a tertiary center in Japan between April 1, 2018, and April 30, 2024. This analysis focused on evaluating the first episode of AC during hospitalization. Results A total of 721 patients with cholangitis underwent ERCP. ESBL-E was detected as the causative pathogen in 22 cases, whereas CAE was identified in 113 cases. Patients with CAE experienced a significantly higher recurrence rate within 60 days (15.9% vs. 4.3%, p < 0.001) and required more frequent escalation to broad-spectrum antibiotics (19.5% vs. 8.7%, p = 0.001). No significant differences in clinical outcomes were observed between patients with and without ESBL-E. Multivariate analysis identified independent risk factors for AC caused by ESBL-E: previous antibiotic use within 90 days, dialysis, and residence in nursing homes. For CAE, independent risk factors included antibiotic use within 90 days and a history of endoscopic sphincterotomy (EST). Conclusion In AC, recent antibiotic use, dialysis, and institutionalization are associated with ESBL-E, whereas recent antibiotic use and a history of EST are linked to CAE.

Journal Section:
Microbiota
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.